LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19)

Exclusion Criteria

• •3. Patients must present with moderate to severe illness as defined below:
• •* Moderate illness: Patients who have evidence of lower respiratory disease by clinical assessment or imaging and an oxygen saturation (SpO2) \> 93% on room air at sea level
• •* Severe illness: Patients who have a respiratory frequency \> 30 breaths per minute (bpm), SpO2 ≤ 93% on room air at sea level, ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (PaO2/FiO2) \< 300, or lung infiltrates \> 50%.
• •4. APACHE II score \< 20 or establishment of survivability of the patient beyond 48 hours following randomization
• •5. Therapies which have been shown to be beneficial and are included in standard COVID-19 treatment guidelines (e.g. those of WHO or NIH, or institutional guidelines) are permitted
• •6. Sexually active women of child-bearing potential (WCBP) must be using a medically acceptable method of birth control throughout the study and for at least 1 day following the end of study, and have a negative urine pregnancy test at the Screening visit. A WCBP is defined as a female who is biologically capable of becoming pregnant. A medically acceptable method of birth control includes intrauterine devices in place for at least 3 months, surgical sterilization, or the implant. In patients who are not sexually active, abstinence is an acceptable form of birth control and urine will be tested per protocol. Women who are of nonchild-bearing potential, i.e., post-menopause, must have this condition captured in their medical history. Pregnant women and nursing mothers are excluded from this study.
• •7. Patient or LAR is available and willing to give written informed consent, after being properly informed of the nature and risks of the study and prior to engaging in any study-related procedures.
• •1. Known sensitivity, allergy, or previous exposure to LSALT peptide.
• •2. Exposure to any investigational drug or device \<90 days prior to entry into study.
• •3. Treatment with immunomodulators or immunosuppressant drugs, including but not limited to IL-6 inhibitors, TNF inhibitors, anti-IL-1 immunomodulators, and JAK inhibitors within five half-lives or 30 days (whichever is longer) prior to randomization and throughout the study period. However, should any of these treatments become standard-of-care and incorporated into clinical treatment guidelines (e.g. those of WHO or NIH), the treatment is permitted. Further, low-dose oral prednisone (\<20 mg/day) and inhaled steroids (e.g. treatment of asthma) are allowed in the study.
• •4. Anticipated transfer to another hospital or medical center within 72 hours, which is not a study site.
• •5. Uncontrolled of poorly treated active hepatitis B (HBV), hepatitis C (HepC), or HIV infection. Those subjects who are positive for HBV, HepC, or HIV but are well-controlled with low viral loads are allowed to participate in this study:
• •* HBV low viral load defined as \<20,000 IU/mL
• •* HepC low viral load defined as \<800,000 IU/mL
• •* HIV low viral load defined as \<5000 copies/mL
• •6. Participation in another drug or device study at any time during this study, for example:
• •* Ulinastatin 200,000 IU or greater
• •* High dose intravenous Vitamin C
• •* Budesonide and formoterol
• •* Bevacizumab to prevent ARDS
• •* Dornase alfa to reduce hypoxemia in ventilated trauma patients.